[ Inside the business ]

TDOC stock analysis

TDOC · Teladoc Health, Inc.

Services-offices and clinics of doctors of medicine. Shrinking 3%.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 0.2× sales in 5 yrs. Evidence: sales −3% · loss shrinking.

01 What's priced in?0.2× sales in 5 yrs
Sales now$2.5B
Needed in 5 yrs$548M
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Five Largest Customers: 31%
Five Largest Customers 31%Everyone else
Prepaid $71MSales −3%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Loss shrinking: −7¢ per $1
'21'22'23'24'25−7¢
Before running costs: 67% → 69%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +3.5%/yrDebt $0
07 What could break it?1 to watch
  • Moves strongly with the 10Y yield

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth −2%, −4%, then −3% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 1.2× the market. In the 2022 rate shock it fell 72% while the market fell 24%. Debt is covered by cash.

Speculative check

Not classified.

Not Self-funding because of: operating loss, net loss, loss in the latest quarter, and more.

What they sell

77% Access Fees Revenue.

Access Fees Revenue 77% · Other.. 23% (latest quarter)

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.7× the economy.

The government expects its industry, offices of physicians, to grow 3.4% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

0 of 10 years.

Returns beat its 7.8% cost of capital in 0 of the last 10 years. Gross margin went from 74% to 69%.

Future bets

11% on research.

$268M a year on R&D. $6M on equipment and buildings.

All figures from Teladoc Health, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.